Preamble
Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, based on systematic methods to evaluate and classify evidence, provide a cornerstone of quality cardiovascular care.
In response to reports from the Institute of Medicine (1, 2) and a mandate to evaluate new knowledge and maintain relevance at the point of care, the ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) modified its methodology (3) (4) (5) . The relationships among guidelines, data standards, appropriate use criteria, and performance measures are addressed elsewhere (5) .
Intended Use
Practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations may have a broader target. Although guidelines may be used to inform regulatory or payer decisions, the intent is to improve quality of care and align with patients' interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances, and should not replace clinical judgment. Guidelines are reviewed annually by the Task Force and are official policy of the ACC and AHA. Each guideline is considered current until it is updated, revised, or superseded by published addenda, statements of clarification, focused updates, or revised full-text guidelines. To ensure that guidelines remain current, new data are reviewed biannually to determine whether recommendations should be modified. In general, full revisions are posted in 5-year cycles (3) (4) (5) (6) .
Modernization
Processes have evolved to support the evolution of guidelines as "living documents" that can be dynamically updated. This process delineates a recommendation to address a specific clinical question, followed by concise text (ideally <250 words) and hyperlinked to supportive evidence. This approach accommodates time constraints on busy clinicians and facilitates easier access to recommendations via electronic search engines and other evolving technology.
Evidence Review
Writing committee members review the literature; weigh the quality of evidence for or against particular tests, treatments, or procedures; and estimate expected health outcomes. In developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data (3) (4) (5) (6) (7) . Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only selected references are cited.
The Task Force recognizes the need for objective, independent Evidence Review Committees (ERCs) that include methodologists, epidemiologists, clinicians, and biostatisticians who systematically survey, abstract, and assess the evidence to address systematic review questions posed in the PICOTS format (P=population, I=intervention, C=comparator, O=outcome, T=timing, S=setting) (2, (4) (5) (6) . Practical considerations, including time and resource constraints, limit the ERCs to evidence that is relevant to key clinical questions and lends itself to systematic review and analysis that could affect the strength of corresponding recommendations.
Guideline-Directed Management and Treatment
The term "guideline-directed management and therapy" (GDMT) refers to care defined mainly by ACC/AHA Class I recommendations. For these and all recommended drug treatment regimens, the reader should confirm dosage with product insert material and carefully evaluate for contraindications and interactions. Recommendations are limited to treatments, drugs, and devices approved for clinical use in the United States.
Class of Recommendation and Level of Evidence
The Class of Recommendation (COR; i.e., the strength of the recommendation) encompasses the anticipated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates evidence supporting the effect of the intervention on the basis of the type, quality, quantity, and consistency of data from clinical trials and other reports (Table 1) (3) (4) (5) . Unless otherwise stated, recommendations are sequenced by COR and then by LOE. Where comparative data exist, preferred strategies take precedence. When >1 drug, strategy, or therapy exists within the same COR and LOE and no comparative data are available, options are listed alphabetically.
Relationships With Industry and Other Entities
The ACC and AHA sponsor the guidelines without commercial support, and members volunteer their time. The Task Force zealously avoids actual, potential, or perceived conflicts of interest that might arise through relationships with industry or other entities (RWI). All writing committee members and reviewers are required to disclose current industry relationships or personal interests, from 12 months before initiation of the writing effort. Management of RWI involves selecting a balanced writing committee and assuring that the chair and a majority of committee members have no relevant RWI (Appendix 1). Members are restricted with regard to writing or voting on sections to which their RWI apply. For transparency, members' comprehensive disclosure information is available online. Comprehensive disclosure information for the Task Force is also available online.
The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds representing different geographic regions, sexes, ethnicities, intellectual perspectives/biases, and scopes of clinical practice, and by inviting organizations and professional societies with related interests and expertise to participate as partners or collaborators.
Individualizing Care in Patients With Associated Conditions and Comorbidities
Managing patients with multiple conditions can be complex, especially when recommendations applicable to coexisting illnesses are discordant or interacting (8) . The guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances. The recommendations should not replace clinical judgment.
Clinical Implementation
Management in accordance with guideline recommendations is effective only when followed. Adherence to recommendations can be enhanced by shared decision making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated conditions and comorbidities. Consequently, circumstances may arise in which deviations from these guidelines are appropriate.
The reader is encouraged to consult the full-text guideline (9) for additional guidance and details with regard to 
Introduction

Methodology and Evidence Review
The recommendations listed in this guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, was conducted from January through September 2015. Key search words included but were not limited to the following: acute limb ischemia, angioplasty, ankle-brachial index, anticoagulation, antiplatelet therapy, atypical leg symptoms, blood pressure lowering/hypertension, bypass graft/bypass grafting/surgical bypass, cilostazol, claudication/intermittent claudication, critical limb ischemia/severe limb ischemia, diabetes, diagnostic testing, endovascular therapy, exercise rehabilitation/exercise therapy/exercise training/supervised exercise, lower extremity/foot wound/ ulcer, peripheral artery disease/peripheral arterial disease/peripheral vascular disease/lower extremity arterial disease, smoking/smoking cessation, statin, stenting, and vascular surgery. Additional relevant studies published through September 2016, during the guideline writing process, were also considered by the writing committee, and added to the evidence tables when appropriate. The final evidence tables included in the Online Data Supplement summarize the evidence utilized by the writing committee to formulate recommendations. Additionally, the writing committee reviewed documents related to lower extremity PAD previously published by the ACC and AHA (10, 11) . References selected and published in this document are representative and not all-inclusive.
As stated in the Preamble, the ACC/AHA guideline methodology provides for commissioning an independent ERC to address systematic review questions (PICOTS format) to inform recommendations developed by the writing committee. All other guideline recommendations (not based on the systematic review questions) were also subjected to an extensive evidence review process. For this guideline, the writing committee in conjunction with the Task Force and ERC Chair identified the following systematic review questions: 1) Is antiplatelet therapy beneficial for prevention of cardiovascular events in the patient with symptomatic or asymptomatic lower extremity PAD? 2) What is the effect of revascularization, compared with optimal medical therapy and exercise training, on functional outcome and quality of life (QoL) among patients with claudication? Each question has been the subject of recently published, systematic evidence reviews (12-14). The quality of these evidence reviews was appraised by the ACC/ AHA methodologist and a vendor contracted to support this process (Doctor Evidence [Santa Monica, CA]). Few substantive randomized or nonrandomized studies had been published after the end date of the literature searches used for the existing evidence reviews, so the ERC concluded that no additional systematic review was necessary to address either of these critical questions.
A third systematic review question was then identified: 3) Is one revascularization strategy (endovascular or surgical) associated with improved cardiovascular and limbrelated outcomes in patients with critical limb ischemia (CLI)? This question had also been the subject of a highquality systematic review that synthesized evidence from observational data and an RCT (15); additional RCTs addressing this question are ongoing (16-18). The writing committee and the Task Force decided to expand the survey to include more relevant randomized and observational studies. Based on evaluation of this additional evidence the ERC decided that further systematic review was not needed to inform the writing committee on this question. Hence, the ERC and writing committee concluded that available systematic reviews could be used to inform the development of recommendations addressing each of the 3 systematic review questions specified above. The members of the Task Force and writing committee thank the members of the ERC that began this process and their willingness to participate in this volunteer effort. They include Aruna Pradhan, MD, MPH (ERC Chair); Natalie Evans, MD; Peter Henke, MD; Dharam J. Kumbhani, MD, SM, FACC; and Tamar Polonsky, MD.
Organization of the Writing Committee
The writing committee consisted of clinicians, including noninvasive and interventional cardiologists, exercise physiologists, internists, interventional radiologists, vascular nurses, vascular medicine specialists, and vascular surgeons, as well as clinical researchers in the field of vascular disease, a nurse (in the role of patient representative), and members with experience in epidemiology and/or health services research. 
Document Review and Approval
This document was reviewed by 2 official reviewers nominated by the ACC and AHA; 1 to 2 reviewers each from the American Association of Cardiovascular 
Scope of Guideline
Lower extremity PAD is a common cardiovascular disease that is estimated to affect approximately 8.5 million Americans above the age of 40 years and is associated with significant morbidity, mortality, and QoL impairment (19). It has been estimated that 202 million people worldwide have PAD (20). The purpose of this document is to provide a contemporary guideline for diagnosis and management of patients with lower extremity PAD. This document supersedes recommendations related to lower extremity PAD in the "ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease" (10) and the "2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease" (11). The scope of this guideline is limited to atherosclerotic disease of the lower extremity arteries (PAD) and includes disease of the aortoiliac, femoropopliteal, and infrapopliteal arterial segments. It does not address nonatherosclerotic causes of lower extremity arterial disease, such as vasculitis, fibromuscular dysplasia, physiological entrapment syndromes, cystic adventitial disease, and other entities. Future guidelines will address aneurysmal disease of the abdominal aorta and lower extremity arteries and diseases of the renal and mesenteric arteries.
For the purposes of this guideline, key terms associated with PAD are defined in Table 2 . Table 2 . Definition of PAD Key Terms.
Term Definition
Claudication Fatigue, discomfort, cramping, or pain of vascular origin in the muscles of the lower extremities that is consistently induced by exercise and consistently relieved by rest (within 10 min).
Acute limb ischemia (ALI) Acute (<2 wk), severe hypoperfusion of the limb characterized by these features: pain, pallor, pulselessness, poikilothermia (cold), paresthesias, and paralysis.
• One of these categories of ALI is assigned (Section 10): 
Tissue loss Type of tissue loss:
• Minor-nonhealing ulcer, focal gangrene with diffuse pedal ischemia.
• Major-extending above transmetatarsal level; functional foot no longer salvageable (21).
Critical limb ischemia (CLI)
A condition characterized by chronic (⩾2 wk) ischemic rest pain, nonhealing wound/ulcers, or gangrene in 1 or both legs attributable to objectively proven arterial occlusive disease.
• The diagnosis of CLI is a constellation of both symptoms and signs. Arterial disease can be proved objectively with ABI, TBI, TcPO 2 , or skin perfusion pressure. Supplementary parameters, such as absolute ankle and toe pressures and pulse volume recordings, may also be used to assess for significant arterial occlusive disease. However, a very low ABI or TBI does not necessarily mean the patient has CLI. The term CLI implies chronicity and is to be distinguished from ALI (23).
In-line blood flow
Direct arterial flow to the foot, excluding collaterals.
Functional status
Patient's ability to perform normal daily activities required to meet basic needs, fulfill usual roles, and maintain health and well-being. Walking ability is a component of functional status.
Nonviable limb
Condition of extremity (or portion of extremity) in which loss of motor function, neurological function, and tissue integrity cannot be restored with treatment.
Salvageable limb
Condition of extremity with potential to secure viability and preserve motor function to the weight-bearing portion of the foot if treated.
Term Definition
Structured exercise program Planned program that provides individualized recommendations for type, frequency, intensity, and duration of exercise.
• Program provides recommendations for exercise progression to assure that the body is consistently challenged to increase exercise intensity and levels as functional status improves over time. • There are 2 types of structured exercise program for patients with PAD:
1. Supervised exercise program 2. Structured community-or home-based exercise program Supervised exercise program Structured exercise program that takes place in a hospital or outpatient facility in which intermittent walking exercise is used as the treatment modality.
• Program can be standalone or can be made available within a cardiac rehabilitation program.
• Program is directly supervised by qualified healthcare provider(s).
• Training is performed for a minimum of 30 to 45 min per session, in sessions performed at least 3 times/wk for a minimum of 12 wk (24-34). Patients may not initially achieve these targets, and a treatment goal is to progress to these levels over time. • Training involves intermittent bouts of walking to moderate-to-maximum claudication, alternating with periods of rest. • Warm-up and cool-down periods precede and follow each session of walking.
Structured community-or home-based exercise program
Structured exercise program that takes place in the personal setting of the patient rather than in a clinical setting (29,35-39).
• Program is self-directed with the guidance of healthcare providers who prescribe an exercise regimen similar to that of a supervised program. • Patient counseling ensures that patients understand how to begin the program, how to maintain the program, and how to progress the difficulty of the walking (by increasing distance or speed). • Program may incorporate behavioral change techniques, such as health coaching and/or use of activity monitors.
Emergency versus urgent
• An emergency procedure is one in which life or limb is threatened if the patient is not in the operating room or interventional suite and/or where there is time for no or very limited clinical evaluation, typically within <6 h. • An urgent procedure is one in which there may be time for a limited clinical evaluation, usually when life or limb is threatened if the patient is not in the operating room or interventional suite, typically between 6 and 24 h. 
Clinical Assessment For PAD
Evaluating the patient at increased risk of PAD (Table 3) begins with the clinical history, review of symptoms, and physical examination. The symptoms and signs of PAD are variable. Patients with PAD may experience the classic symptom of claudication or may present with advanced disease, including CLI. Studies have demonstrated that the majority of patients with confirmed PAD do not have typical claudication but have other non-joint-related limb symptoms (atypical leg symptoms) or are asymptomatic (40, 41) . Patients with PAD who have atypical leg symptoms or no symptoms may have functional impairment comparable to patients with claudication (42) . The vascular examination for PAD includes pulse palpation, auscultation for femoral bruits, and inspection of the legs and feet. Lower extremity pulses are assessed and rated as follows: 0, absent; 1, diminished; 2, normal; or 3, bounding. See Table 4 for history and physical examination findings suggestive of PAD. To confirm the diagnosis of PAD, abnormal physical examination findings must be confirmed with diagnostic testing (Section 3), generally with the anklebrachial index (ABI) as the initial test.
Patients with confirmed diagnosis of PAD are at increased risk for subclavian artery stenosis (43) (44) (45) ). An inter-arm blood pressure difference of >15 to 20 mm Hg is abnormal and suggestive of subclavian (or innominate) artery stenosis. Measuring blood pressure in both arms identifies the arm with the highest systolic pressure, a requirement for accurate measurement of the ABI (46) . Identification of unequal blood pressures in the arms also allows for more accurate measurement of blood pressure in the treatment of hypertension (i.e., blood pressure is taken at the arm with higher measurements).
See Online Data Supplements 1 and 2 for data supporting Section 2. Table 3 . Patients at Increased Risk of PAD.
• Age ⩾65 y • Age 50-64 y, with risk factors for atherosclerosis (e.g., diabetes mellitus, history of smoking, hyperlipidemia, hypertension) or family history of PAD (52) • Age <50 y, with diabetes mellitus and 1 additional risk factor for atherosclerosis • Individuals with known atherosclerotic disease in another vascular bed (e.g., coronary, carotid, subclavian, renal, mesenteric artery stenosis, or AAA)
AAA indicates abdominal aortic aneurysm; PAD, peripheral artery disease. 
History and Physical Examination: Recommendations
Recommendations for History and Physical Examination COR LOE RECOMMENDATIONS I B-NR Patients at increased risk of PAD (Table 3) should undergo a comprehensive medical history and a review of symptoms to assess for exertional leg symptoms, including claudication or other walking impairment, ischemic rest pain, and nonhealing wounds (40) (41) (42) (47) (48) (49) . I B-NR Patients at increased risk of PAD (Table 3) should undergo vascular examination, including palpation of lower extremity pulses (i.e., femoral, popliteal, dorsalis pedis, and posterior tibial), auscultation for femoral bruits, and inspection of the legs and feet (48, 50, 51) . I B-NR Patients with PAD should undergo noninvasive blood pressure measurement in both arms at least once during the initial assessment (43-45).
Diagnostic Testing For The Patient With Suspected Lower Extremity Pad (Claudication Or CLI): Recommendations
History or physical examination findings suggestive of PAD need to be confirmed with diagnostic testing. The resting ABI is the initial diagnostic test for PAD and may be the only test required to establish the diagnosis and institute GDMT. The resting ABI is a simple, noninvasive test that is obtained by measuring systolic blood pressures at the arms (brachial arteries) and ankles (dorsalis pedis and posterior tibial arteries) in the supine position by using a Doppler device. The ABI of each leg is calculated by dividing the higher of the dorsalis pedis pressure or posterior tibial pressure by the higher of the right or left arm blood pressure (46) . Segmental lower extremity blood pressures and Doppler or plethysmographic waveforms (pulse volume recordings) are often performed along with the ABI and can be used to localize anatomic segments of disease (e.g., aortoiliac, femoropopliteal, infrapopliteal) (22,53,54). Depending on the clinical presentation (e.g., claudication or CLI) and the resting ABI values, additional physiological testing studies may be indicated, including exercise treadmill ABI testing, measurement of the toe-brachial index (TBI), and additional perfusion assessment measures (e.g., transcutaneous oxygen pressure [TcPO 2 ], or skin perfusion pressure [SPP]). Exercise treadmill ABI testing is important to objectively measure functional limitations attributable to leg symptoms and is useful in establishing the diagnosis of lower extremity PAD in the symptomatic patient when resting ABIs are normal or borderline (54) (55) (56) (57) (58) (59) . The TBI is used to establish the diagnosis of PAD in the setting of noncompressible arteries (ABI >1.40) and may also be used to assess perfusion in patients with suspected CLI. Studies for anatomic imaging assessment (duplex ultrasound, computed tomography angiography [CTA], or magnetic resonance angiography [MRA], invasive angiography) are generally reserved for highly symptomatic patients in whom revascularization is being considered. Depending on the modality, these studies may confer procedural risk.
See Table 5 for alternative causes of leg pain in the patient with normal ABI and physiological testing; Figure  1 for the algorithm on diagnostic testing for suspected PAD and claudication; Table 6 for alternative causes of nonhealing wounds in patients without PAD; Figure 2 for the algorithm on diagnostic testing for suspected CLI; and Online Data Supplements 3 to 7 for data supporting Section 3. (Table 3) and without history or physical examination findings suggestive of PAD (Table 4) , the ABI is not recommended (87,90).
Physiological Testing
Recommendations for Physiological Testing Colors correspond to Class of Recommendation in Table 1 
Imaging for Anatomic Assessment
Recommendations for Imaging for Anatomic Assessment 
Screening For Atherosclerotic Disease In Other Vascular Beds For The Patient With PAD: Recommendations
See Online Data Supplement 8 for data supporting Section 4.
Abdominal Aortic Aneurysm
PAD has been recognized as a risk factor for abdominal aortic aneurysm (AAA). In observational studies, the prevalence of AAA (aortic diameter ⩾3 cm) was higher in patients with symptomatic PAD than in the general population (107, 108) and in a population of patients with atherosclerotic risk factors (109) . The prevalence of AAA among patients with PAD increased with age, beginning in patients ⩾55 years of age, and was highest in patients ⩾75 years of age (107) . There are no data on AAA screening in patients with asymptomatic PAD. This section refers to screening patients with symptomatic PAD for AAA. Recommendations for screening the general population with risk factors for AAA (based on age, sex, smoking history, and family history) have been previously published (10) .
Recommendation for Abdominal Aortic Aneurysm
Screening for Asymptomatic Atherosclerosis in Other Arterial Beds (Coronary, Carotid, and Renal Arteries)
The prevalence of atherosclerosis in the coronary, carotid, and renal arteries is higher in patients with PAD than in those without PAD (109) (110) (111) (112) (113) (114) (115) . However, intensive atherosclerosis risk factor modification in patients with PAD is justified regardless of the presence of disease in other arterial beds. Thus, the only justification for screening for disease in other arterial beds is if revascularization results in a reduced risk of myocardial infarction (MI), stroke, or death, and this has never been shown. Currently, there is no evidence to demonstrate that screening all patients with PAD for asymptomatic atherosclerosis in other arterial beds improves clinical outcome. Intensive treatment of risk factors through GDMT is the principle method for preventing adverse cardiovascular ischemic events from asymptomatic disease in other arterial beds.
Medical Therapy For The Patient With PAD: Recommendations
Patients with PAD should receive a comprehensive program of GDMT, including structured exercise and lifestyle modification, to reduce cardiovascular ischemic events and improve functional status. Smoking cessation is a vital component of care for patients with PAD who continue to smoke. A guideline-based program of pharmacotherapy to reduce cardiovascular ischemic events and limb-related events should be prescribed for each patient with PAD and is customized to individual risk factors, such as whether the patient also has diabetes mellitus. Pharmacotherapy for the patient with PAD includes antiplatelet and statin agents and is customized to additional risk factors, such as whether the patient also has diabetes mellitus or hypertension. Previous studies have demonstrated that patients with PAD are less likely to receive GDMT than patients with other forms of cardiovascular disease, including coronary artery disease (116) (117) (118) . Cilostazol is an effective medical therapy for treatment of leg symptoms and walking impairment due to claudication (119) . However, side effects include headache, diarrhea, dizziness, and palpitations and in 1 trial, 20% of patients discontinued cilostazol within 3 months (120) . See Online Data Supplements 13 to 19 for data supporting Section 5.
Antiplatelet, Statin, Antihypertensive Agents, and Oral Anticoagulation
Recommendations for Antiplatelet, Statin, and Antihypertensive Agents
COR LOE RECOMMENDATIONS
Antiplatelet Agents I A Antiplatelet therapy with aspirin alone (range 75-325 mg per day) or clopidogrel alone (75 mg per day) is recommended to reduce MI, stroke, and vascular death in patients with symptomatic PAD (121) (122) (123) (124) . IIa C-EO In asymptomatic patients with PAD (ABI ⩽0.90), antiplatelet therapy is reasonable to reduce the risk of MI, stroke, or vascular death. IIb B-R In asymptomatic patients with borderline ABI (0.91-0.99), the usefulness of antiplatelet therapy to reduce the risk of MI, stroke, or vascular death is uncertain (67, 68) . IIb B-R The effectiveness of dual antiplatelet therapy (aspirin and clopidogrel) to reduce the risk of cardiovascular ischemic events in patients with symptomatic PAD is not well established (125, 126) . IIb C-LD Dual antiplatelet therapy (aspirin and clopidogrel) may be reasonable to reduce the risk of limb-related events in patients with symptomatic PAD after lower extremity revascularization (127) (128) (129) (130) . IIb B-R The overall clinical benefit of vorapaxar added to existing antiplatelet therapy in patients with symptomatic PAD is uncertain (131) (132) (133) (134) .
Statin Agents I
A Treatment with a statin medication is indicated for all patients with PAD (88, [135] [136] [137] [138] [139] .
Antihypertensive Agents I
A Antihypertensive therapy should be administered to patients with hypertension and PAD to reduce the risk of MI, stroke, heart failure, and cardiovascular death (140) (141) (142) (143) (144) . IIa A The use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers can be effective to reduce the risk of cardiovascular ischemic events in patients with PAD (143, 145, 146) . Oral Anticoagulation IIb B-R The usefulness of anticoagulation to improve patency after lower extremity autogenous vein or prosthetic bypass is uncertain (147) (148) (149) .
III: Harm
A Anticoagulation should not be used to reduce the risk of cardiovascular ischemic events in patients with PAD (148,150-152).
Smoking Cessation
Recommendations 
Glycemic Control
Recommendations for Glycemic Control 
Homocysteine Lowering
Recommendation for Homocysteine Lowering 
Influenza Vaccination
Recommendation for Influenza Vaccination 
Structured Exercise Therapy: Recommendations
Structured exercise therapy is an important element of care for the patient with PAD. Components of structured exercise programs for PAD are outlined in Table 7 . The data supporting the efficacy of supervised exercise programs as an initial treatment for claudication continue to develop and remain convincing, building on many earlier RCTs (28-34,36, 169, 170) . Trials with long-term follow-up from 18 months (25,26) to 7 years (24) have demonstrated a persistent benefit of supervised exercise in patients with claudication. The risk-benefit ratio for supervised exercise in PAD is favorable, with an excellent safety profile in patients screened for absolute contraindications to exercise such as exercise-limiting cardiovascular disease, amputation or wheelchair confinement, and other major comorbidities that would preclude exercise (24,27,37,171-174). CLI indicates critical limb ischemia.Studies supporting structured community-or home-based programs for patients with PAD are more recent than studies supporting supervised exercise programs and have provided strong evidence in support of the community-or home-based approach (35,37,39,80,86,171). Unstructured community-or homebased walking programs that consist of providing general recommendations to patients with claudication to simply walk more are not efficacious (38) .
See Online Data Supplements 32 and 33 for data supporting Section 6. 
Recommendations for Structured Exercise Therapy
Supervised exercise program (COR I, LOE A)
• Program takes place in a hospital or outpatient facility.
• Program uses intermittent walking exercise as the treatment modality.
• Program can be standalone or within a cardiac rehabilitation program.
• Training is performed for a minimum of 30-45 min/session; sessions are performed at least 3 times/wk for a minimum of 12 wk (24-34). • Training involves intermittent bouts of walking to moderate-to-maximum claudication, alternating with periods of rest.
• Warm-up and cool-down periods precede and follow each session of walking. Structured community-or home-based exercise program (COR IIa, LOE A) • Program takes place in the personal setting of the patient rather than in a clinical setting (29,35-39).
• Program is self-directed with guidance of healthcare providers.
• Healthcare providers prescribe an exercise regimen similar to that of a supervised program.
• Patient counseling ensures understanding of how to begin and maintain the program and how to progress the difficulty of the walking (by increasing distance or speed 
Minimizing Tissue Loss In Patients With PAD Recommendations
Prevention of wounds through patient education, foot examination, and prompt recognition of foot infection is important to minimize tissue loss among patients with PAD. Education includes teaching patients about healthy foot behaviors (e.g., daily inspection of feet, wearing of shoes and socks; avoidance of barefoot walking), the selection of proper footwear, and the importance of seeking medical attention for new foot problems (177) . Educational efforts are especially important for patients with PAD who have diabetes mellitus with peripheral neuropathy. Foot infections (infection of any of the structures distal to the malleoli) may include cellulitis, abscess, fasciitis, tenosynovitis, septic joint space infection, and osteomyelitis.
Because of the consequences associated with untreated foot infection-especially in the presence of PAD-clinicians should maintain a high index of suspicion (178) . Foot infection is suspected if the patient presents with local pain or tenderness; periwound erythema; periwound edema, induration, or fluctuance; pretibial edema; any discharge (especially purulent); foul odor; visible bone or a wound that probes to bone; or signs of a systemic inflammatory response (including temperature >38°C or <36°C, heart rate >90/min, respiratory rate >20/min or Paco 2 <32 mm Hg, white blood cell count >12,000 or <4,000/mcL or >10% immature forms) (179) . It is recognized that the presence of diabetes mellitus with peripheral neuropathy and PAD may make the presentation of foot infection more subtle than in patients without these problems.
See Online Data Supplement 34 for data supporting Section 7.
COR
LOE RECOMMENDATIONS I C-LD Patients with PAD and diabetes mellitus should be counseled about self-foot examination and healthy foot behaviors (177, 180) . I C-LD In patients with PAD, prompt diagnosis and treatment of foot infection are recommended to avoid amputation (178, 179, (181) (182) (183) . IIa C-LD In patients with PAD and signs of foot infection, prompt referral to an interdisciplinary care team (Table 8) can be beneficial (178, 184, 185) . IIa C-EO It is reasonable to counsel patients with PAD without diabetes mellitus about self-foot examination and healthy foot behaviors. IIa C-EO Biannual foot examination by a clinician is reasonable for patients with PAD and diabetes mellitus.
Recommendations for Minimizing Tissue Loss in Patients With PAD
Revascularization for Claudication: Recommendations
A minority of patients with claudication (estimated at <10% to 15% over 5 years or more) will progress to CLI (186) (187) (188) (189) . Therefore, the role of revascularization in claudication is improvement in claudication symptoms and functional status, and consequently in QoL, rather than limb salvage. Revascularization is reasonable when the patient who is being treated with GDMT (including structured exercise therapy) presents with persistent lifestylelimiting claudication (13, 25, 26, 190, 191) . Lifestyle-limiting claudication is defined by the patient rather than by any test. It includes impairment of activities of daily living and/or vocational and/or recreational activities due to claudication. An individualized approach to revascularization for claudication is recommended for each patient to optimize outcome. Revascularization is but one component of care for the patient with claudication, inasmuch as each patient should have a customized care plan that also includes medical therapy (Section 5), structured exercise therapy (Section 6), and care to minimize tissue loss (Section 7). If a strategy of revascularization for claudication is undertaken, the revascularization strategy should be evidence based and can include endovascular revascularization, surgery, or both. Due to the variability of ischemic limb symptoms and impact of these symptoms on functional status and QoL, patients should be selected for revascularization on the basis of severity of their symptoms. Factors to consider include a significant disability as assessed by the patient, adequacy of response to medical and structured exercise therapy, status of comorbid conditions, and a favorable risk-benefit ratio. Patient preferences and goals of care are important considerations in the evaluation for revascularization. The revascularization strategy should have a reasonable likelihood of providing durable relief of symptoms. There should be clear discussion with the patient about expected risks and benefits of revascularization, as well as discussion of the durability of proposed procedures. A general recommendation for revascularization as a treatment option for claudication is provided below followed by specific recommendations for endovascular (Section 8.1.1) and surgical (Section 8.1.2) procedures if a revascularization strategy is undertaken.
See Online Data Supplements 35 to 38 for data supporting Section 8.
Revascularization for Claudication
Recommendation for Revascularization for Claudication
Endovascular Revascularization for Claudication. Endovascular techniques to treat claudication include balloon dilation (angioplasty), stents, and atherectomy.
These techniques continue to involve and now include covered stents, drug-eluting stents, cutting balloons, and drug-coated balloons. The technique chosen for endovascular treatment is related to lesion characteristics (e.g., anatomic location, lesion length, degree of calcification) and operator experience. Assessment of the appropriateness of specific endovascular techniques for specific lesions for the treatment of claudication is beyond the scope of this document.
Revascularization is performed on lesions that are deemed to be hemodynamically significant, and stenoses selected for endovascular treatment should have a reasonable likelihood of limiting perfusion to the distal limb. Stenoses of 50% to 75% diameter by angiography may not be hemodynamically significant, and resting or provoked intravascular pressure measurements may be used to determine whether lesions are 
COR LOE RECOMMENDATION
IIa A Revascularization is a reasonable treatment option for the patient with lifestyle-limiting claudication with an inadequate response to GDMT (13, 25, 26, 190, 191) .
significant (192, 193) . Multiple RCTs have compared endovascular procedures to various combinations of medical treatment with or without supervised or unsupervised exercise programs (13, 25, 26, 190, 191, (194) (195) (196) (197) (198) (199) (200) (201) (202) (203) (204) (205) (206) . These trials have used different endpoints and enrolled patients with anatomic disease distribution at different levels. Long-term patency is greater in the aortoiliac than in the femoropopliteal segment. Furthermore, for femoropopliteal disease, durability is diminished with greater lesion length, occlusion rather than stenosis, the presence of multiple and diffuse lesions, poor-quality runoff, diabetes mellitus, chronic kidney disease, renal failure, and smoking (207) (208) (209) (210) .
Recommendations for Endovascular Revascularization for Claudication
COR LOE RECOMMENDATIONS I A Endovascular procedures are effective as a revascularization option for patients with lifestyle-limiting claudication and hemodynamically significant aortoiliac occlusive disease (13, 25, 26, 190, 194, 196, 201) . IIa B-R Endovascular procedures are reasonable as a revascularization option for patients with lifestyle-limiting claudication and hemodynamically significant femoropopliteal disease (190, (197) (198) (199) (200) 205, 206) . IIb C-LD The usefulness of endovascular procedures as a revascularization option for patients with claudication due to isolated infrapopliteal artery disease is unknown (211) (212) (213) .
III: Harm
B-NR Endovascular procedures should not be performed in patients with PAD solely to prevent progression to CLI (186-189,214-216).
Surgical Revascularization for Claudication.
Systematic reviews have concluded that surgical procedures are an effective treatment for claudication and have a positive impact on QoL and walking parameters but have identified sparse evidence supporting the effectiveness of surgery compared with other treatments (12, 191, 217, 218) . Although symptom and patency outcomes for surgical interventions may be superior to those for less invasive endovascular treatments, surgical interventions are also associated with greater risk of adverse perioperative events (219) (220) (221) (222) (223) (224) (225) . Treatment selection should therefore be individualized on the basis of the patient's goals, perioperative risk, and anticipated benefit. Surgical procedures for claudication are usually reserved for individuals who a) do not derive adequate benefit from nonsurgical therapy, b) have arterial anatomy favorable to obtaining a durable result with surgery, and c) have acceptable risk of perioperative adverse events. Acceptable risk is defined by the individual patient and provider on the basis of symptom severity, comorbid conditions, and appropriate GDMT risk evaluation. The superficial femoral and proximal popliteal arteries are the most common anatomic sites of stenosis or occlusion among individuals with claudication. Femoralpopliteal bypass is therefore one of the most common surgical procedures for claudication. The type of conduit and site of popliteal artery anastomosis (above versus below knee) are major determinants of outcomes associated with femoral-popliteal bypass. Systematic reviews and meta-analyses have identified a clear and consistent primary patency benefit for autogenous vein versus prosthetic grafts for popliteal artery bypass (226, 227) .
Recommendations for Surgical Revascularization for Claudication
COR LOE RECOMMENDATIONS I A When surgical revascularization is performed, bypass to the popliteal artery with autogenous vein is recommended in preference to prosthetic graft material (226) (227) (228) (229) (230) (231) (232) (233) (234) . IIa B-NR Surgical procedures are reasonable as a revascularization option for patients with lifestyle-limiting claudication with inadequate response to GDMT, acceptable perioperative risk, and technical factors suggesting advantages over endovascular procedures (190, 230, (235) (236) (237) . III: Harm B-R Femoral-tibial artery bypasses with prosthetic graft material should not be used for the treatment of claudication (238) (239) (240) . III: Harm B-NR Surgical procedures should not be performed in patients with PAD solely to prevent progression to CLI (186) (187) (188) (189) 241 ).
Management of CLI: Recommendations
Patients with CLI are at increased risk of amputation and major cardiovascular ischemic events. Care of the patient with CLI includes evaluation for revascularization and wound healing therapies, with the objective to minimize tissue loss, completely heal wounds, and preserve a functional foot. Medical therapy to prevent cardiovascular ischemic events is also an important component of care for the patient with CLI (Section 5). See Online Data Supplements 39 and 40 for data supporting Section 9.
Revascularization for CLI
The goal of surgical or endovascular revascularization in CLI is to provide in-line blood flow to the foot through at least 1 patent artery, which will help decrease ischemic pain and allow healing of any wounds, while preserving a functional limb. The BASIL (Bypass versus Angioplasty in Severe Ischemia of the Leg) RCT (242, 243) demonstrated that endovascular revascularization is an effective option for patients with CLI as compared with open surgery. The primary endpoint of amputation-free survival was the same in the endovascular and surgical arms. Of note, the endovascular arm used only percutaneous transluminal angioplasty (242, 243) . Multiple RCTs comparing contemporary surgical and endovascular treatment for patients with CLI are ongoing (16, 17, 18) . Table 9 addresses factors that may prompt an endovascular versus surgical approach to the patient with CLI.
The angiosome concept has been described in the literature and entails establishing direct blood flow to the infrapopliteal artery directly responsible for perfusing the region of the leg or foot with the nonhealing wound. Multiple retrospective studies and 1 small nonrandomized prospective study assessing the efficacy of this concept have been published (245) (246) (247) (248) (249) (250) (251) (252) (253) (254) (255) (256) (257) . Meta-analyses of these studies found improved wound healing and limb salvage with angiosome-guided therapy but cautioned that the quality of the evidence was low (258, 259) . Although the angiosome concept is theoretically satisfying, randomized data comparing the establishment of in-line flow versus angiosome-guided therapy have yet to be published. Furthermore, there is no evidence yet to demonstrate the potential benefit of treating additional infrapopliteal arteries once in-line flow has been established in one artery, regardless of angiosome. Table 9 . Therapy for CLI: Findings That Prompt Consideration of Surgical or Endovascular Revascularization.
Findings That Favor Consideration of Surgical Revascularization Examples
Factors associated with technical failure or poor durability with endovascular treatment Lesion involving common femoral artery, including origin of deep femoral artery Long segment lesion involving the below-knee popliteal and/ or infrapopliteal arteries in a patient with suitable single-segment autogenous vein conduit Diffuse multilevel disease that would require endovascular revascularization at multiple anatomic levels Small-diameter target artery proximal to site of stenosis or densely calcified lesion at location of endovascular treatment Endovascular treatment likely to preclude or complicate subsequent achievement of in-line blood flow through surgical revascularization
Single-vessel runoff distal to ankle
Findings That Favor Consideration of Endovascular Revascularization Examples
The presence of patient comorbidities may place patients at increased risk of perioperative complications from surgical revascularization. In these patients, an endovascular-first approach should be used regardless of anatomy Patient comorbidities, including coronary ischemia, cardiomyopathy, congestive heart failure, severe lung disease, and chronic kidney disease Patients with rest pain and disease at multiple levels may undergo a staged approach as part of endovascular-first approach (242, 243) . IIa C-LD A staged approach to endovascular procedures is reasonable in patients with ischemic rest pain (261, 262) . IIa B-R Evaluation of lesion characteristics can be useful in selecting the endovascular approach for CLI (263, 264 (228, 231, 234, 265) . I C-LD Surgical procedures are recommended to establish in-line blood flow to the foot in patients with nonhealing wounds or gangrene (266) (267) (268) . IIa B-NR In patients with CLI for whom endovascular revascularization has failed and a suitable autogenous vein is not available, prosthetic material can be effective for bypass to the below-knee popliteal and tibial arteries (269) (270) (271) . IIa C-LD A staged approach to surgical procedures is reasonable in patients with ischemic rest pain (272-274).
Wound Healing Therapies for CLI
A comprehensive plan for treatment of CLI includes a plan to achieve an intact skin surface on a functional foot. The management of patients with CLI and nonhealing wounds includes coordinated efforts for both revascularization and wound healing among members of an interdisciplinary care team ( 
Management of Acute Limb Ischemia: Recommendations
Acute limb ischemia (ALI) is one of the most treatable and potentially devastating presentations of PAD. Timely recognition of arterial occlusion as the cause of an ischemic, cold, painful leg is crucial to successful treatment. The writing committee has used a standard definition of ALI in which symptom duration is <2 weeks ( Patients with ALI should be rapidly evaluated by a vascular specialist if one is available. Depending on local clinical expertise, the vascular specialist may be a vascular surgeon, interventional radiologist, cardiologist, or a general surgeon with specialized training and experience in treating PAD. If such expertise is not locally or rapidly available, there should be strong consideration of transfer of the patient to a facility with such resources. The more advanced the degree of ischemia, the more rapidly the communication (e.g., with regard to potential patient transfer) needs to occur.
ALI is a medical emergency and must be recognized rapidly. The time constraint is due to the period that skeletal muscle will tolerate ischemia-roughly 4 to 6 hours (281). A rapid assessment of limb viability and ability to restore arterial blood flow should be performed by a clinician able to either complete the revascularization or triage the patient (282) . Lower extremity symptoms in ALI can include both pain and loss of function. The longer these symptoms are present, the less likely the possibility of limb salvage (283, 284) . Clinical assessment must include symptom duration, pain intensity, and motor and sensory deficit severity to distinguish a threatened from a nonviable extremity ( Figure  3) . The bedside assessment includes arterial and venous examination with a handheld continuous-wave Doppler because of the inaccuracy of pulse palpation (22). The loss of Dopplerable arterial signal indicates that the limb is threatened. The absence of both arterial and venous Doppler signal indicates that the limb may be irreversibly damaged (nonsalvageable). Comorbidities should be investigated and managed aggressively, but this must not delay therapy. Even in the setting of rapid and effective revascularization, the 1-year morbidity and mortality rates ALI are high (283, 285) .
See Figure 3 for the algorithm on diagnosis and management of ALI and Online Data Supplements 45 to 50 for data supporting Section 10. Colors correspond to Class of Recommendation in Table 1 . ALI indicates acute limb ischemia. 
Clinical Presentation of ALI
Medical Therapy for ALI
Recommendation for ALI Medical Therapy 
Revascularization for ALI
For marginally or immediately threatened limbs (Category IIa and IIb ALI), revascularization should be performed emergently (within 6 hours). For viable limbs (Category I ALI), revascularization should be performed an on urgent basis (within 6-24 hours). The revascularization strategy can range from catheter-directed thrombolysis to surgical thromboembolectomy. Available facilities and clinical expertise are factors that should be considered when determining the revascularization strategy. The technique that will provide the most rapid restoration of arterial flow with the least risk to the patient should be selected. For example, catheter-directed thrombolysis can provide rapid restoration of arterial flow to a viable or marginally threatened limb, particularly in the setting of recent occlusion, thrombosis of synthetic grafts, and stent thrombosis (288) . If this is not available locally, surgical options for timely revascularization should be considered, along with the feasibility of timely transfer to a facility with the necessary expertise. Prolonged duration of ischemia is the most common factor in patients requiring amputation for treatment of ALI. The risks associated with reconstruction outweigh the potential benefit in a limb that is already insensate or immobile because of prolonged ischemia. Patients who have an insensate and immobile limb in the setting of prolonged ischemia (>6 to 8 hours) are unlikely to have potential for limb salvage with revascularization.
Recommendations for Revascularization for ALI
COR
LOE RECOMMENDATIONS I C-LD In patients with ALI, the revascularization strategy should be determined by local resources and patient factors (e.g., etiology and degree of ischemia) (288) (289) (290) . I A Catheter-based thrombolysis is effective for patients with ALI and a salvageable limb (288) (289) (290) (291) (292) . I C-LD Amputation should be performed as the first procedure in patients with a nonsalvageable limb (293, 294) . I C-LD Patients with ALI should be monitored and treated (e.g., fasciotomy) for compartment syndrome after revascularization (293, 294) . IIa B-NR In patients with ALI with a salvageable limb, percutaneous mechanical thrombectomy can be useful as adjunctive therapy to thrombolysis (295) (296) (297) (298) (299) . IIa C-LD In patients with ALI due to embolism and with a salvageable limb, surgical thromboembolectomy can be effective (300) (301) (302) . IIb C-LD The usefulness of ultrasound-accelerated catheter-based thrombolysis for patients with ALI with a salvageable limb is unknown (303-305).
Diagnostic Evaluation of the Cause of ALI
ALI may be related to underlying PAD (including prior lower extremity bypass graft) or may be related to other conditions that can result in ALI through either thrombotic (e.g., hypercoagulable state) or embolic mechanisms. Treatment of ALI should not be delayed for testing for the underlying cause of the limb ischemia because delay from symptom onset to revascularization is a major determinant of outcome (283, 284) . The evaluation of a cardiovascular (i.e., embolic) cause for ALI is most useful in the patient without underlying PAD and can be completed after revascularization. Evaluation for cardiovascular cause includes electrocardiogram or additional heart rhythm monitoring to detect atrial fibrillation, electrocardiogram to detect evidence of MI, and echocardiography to further determine whether there is a cardiac etiology for thromboembolism, such as valvular vegetation, left atrial or left ventricular thrombus, or intracardiac shunt. 
Recommendations for Diagnostic Evaluation of the Cause of ALI
Evidence Gaps and Future Research Directions
In performing the evidence review and in developing the present guidelines, the writing committee identified the following critical evidence gaps and future directions for PAD-related research: 
Advocacy Priorities
The writing committee identified 3 priorities for multisocietal advocacy initiatives to improve health care for patients with PAD. First, the writing committee supports the availability of the ABI as the initial diagnostic test to establish the diagnosis of PAD in patients with history or physical examination findings suggestive of PAD (Table 4) . Although the ABI test is generally reimbursed by third-party payers for patients with classical claudication or lower extremity wounds, payers may not provide reimbursement for the ABI with other findings suggestive of PAD, such as lower extremity pulse abnormalities or femoral bruits. The writing committee affirms the importance of confirming the diagnosis of PAD in such patients to allow for GDMT as delineated in this document. Second, the writing committee supports the vital importance of insuring access to supervised exercise programs for patients with PAD. Although extensive high-quality evidence supports supervised exercise programs to improve functional status and QoL, only a minority of patients with PAD participate in such programs because of lack of reimbursement by third-party payers. Third, the writing committee recognizes the need for incorporation of patient-centered outcomes into the process of regulatory approval of new medical therapies and revascularization technologies. For revascularization technologies, regulatory approval is driven primarily by data on angiographic efficacy (i.e., target-lesion patency) and safety endpoints. The nature of the functional limitation associated with PAD warrants the incorporation of patient-centered outcomes, such as functional parameters and QoL, into the efficacy outcomes for the approval process. 
